Two Fox Chase Clinicians Named to 2022 List of World’s Most Highly Cited Researchers

Dr. Hossein Borghaei and Dr. Elizabeth Plimack
Dr. Hossein Borghaei and Dr. Elizabeth Plimack named to the 2022 list of Highly Cited Researchers by Clarivate, an information and analytics firm focused on research.

PHILADELPHIA (December 2, 2022)—Fox Chase Cancer Center physicians Hossein Borghaei, DO, MS, and Elizabeth Plimack, MD, MS, have been named to the 2022 list of Highly Cited Researchers by Clarivate, an information and analytics firm focused on research.

Borghaei is chief of the Division of Thoracic Medical Oncology and a professor in the Department of Hematology/Oncology at Fox Chase. In addition to being the center’s Deputy Director, Plimack is also chief of the Division of Genitourinary Medical Oncology and a professor in the Department of Hematology/Oncology.

The annual listing recognizes individuals at universities, research institutes, and commercial organizations “who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research,” according to Clarivate.

“We know clinicians and scientists at Fox Chase do cutting-edge, impactful research every day, something that this award highlights,” said Jonathan Chernoff, MD, PhD, Cancer Center Director.

Since its launch in 2001, the Highly Cited Researchers list has identified clinicians and scientists from around the globe who have demonstrated exceptional influence. Clarivate measures this through the publication by researchers of multiple papers frequently cited by their peers during the last decade. The organization uses data from the Web of Science citation index, as well as analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.

Borghaei, who specializes in lung cancer research, is a member of the Cancer Signaling and Microenvironment research program at Fox Chase. His lab concentrates on the development of new cancer treatments, with an emphasis on the use of immunotherapy and monoclonal antibodies. He is also active in clinical trials.

Plimack specializes in the treatment of kidney, bladder, and prostate cancer. Her research efforts focus on the development of new therapies for bladder and kidney cancer. She is also a member of the Nuclear Dynamics and Cancer research program at Fox Chase.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text